This program is intended for healthcare professionals outside the United States only.

Late-onset genetic cholestasis
Login
Register

This program is intended for healthcare professionals outside the United States only.

Popular searches
Popular searches

PFIC trial updates continue to support IBAT inhibitor efficacy and safety

  • Late Onset Genetic Cholestasis, Video

Professor Richard Thompson shares his PFIC poster findings on the long-term efficacy and safety data of the PEDFIC 2 trial and the relationship between serum bile acid and event-free survival in the MARCH and MARCH-ON trials.

This video offers subtitles in English, Portuguese, and Spanish, which can be enabled using the subtitle icon  in the video player.

Enjoyed this? You might like:

  • News article
  • AASLD 2023

Adding bezafibrate to OCA shows treatment promise for PBC

Combining obeticholic acid with bezafibrate 400 mg/day shows therapeutic potential in patients with primary biliary cholangitis in two phase 2 trials.
Find out more
  • News article
  • AASLD 2023

Denosumab performs well against bisphosphonate for PBC-related osteoporosis

Denosumab is comparable to bisphosphonates for treating osteoporosis in patients with primary biliary cholangitis, but with fewer adverse effects.
Find out more
  • News article
  • AASLD 2023

Positive RESPONSE for seladelpar in patients with PBC

RESPONSE trial findings show seladelpar improves markers of disease activity and reduces pruritus in patients with primary biliary cholangitis.
Find out more
  • News article
  • AASLD 2023

ELATIVE: Elafibranor shows treatment efficacy in patients with PBC

ELATIVE trial shows that elafibranor significantly improves biochemical response in patients with primary biliary cholangitis with anti-pruritic benefits.
Find out more
  • News article
  • AASLD 2023

Complete biochemical and POISE response seen with second-line OCA in real-world setting

Obeticholic acid positively affects liver function among patients with primary biliary cholangitis in the second-line treatment setting.
Find out more
  • Video
  • AASLD 2023

Gideon Hirschfield highlights noteworthy findings on PBC

Dr Gideon Hirschfield discusses some of the highlights on primary biliary cholangitis from The Liver Meeting 2023, with a focus on the RESPONSE trial of seladelpar.
Watch now
  • Video
  • AASLD 2023

Kris Kowdley’s analysis of breakthrough research on PBC

Dr Kris Kowdley comments on some of the key data in primary biliary cholangitis, presented at The Liver Meeting 2023, including the ELATIVE trial involving elafibranor.
Watch now
  • Video
  • AASLD 2023

Andreas Kremer discusses advances in second-line obeticholic acid

Prof. Andreas Kremer provides his insights on studies on second-line obeticholic acid presented at The Liver Meeting 2023: its use in a real-world setting and as combination therapy with bezafibrate.
Watch now
Primary Sclerosing Cholangitis (PSC)